B. Riley Has Bullish Estimate for Altimmune FY2025 Earnings

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at B. Riley boosted their FY2025 earnings estimates for Altimmune in a research report issued to clients and investors on Friday, February 28th. B. Riley analyst M. Mamtani now expects that the company will earn $0.86 per share for the year, up from their previous forecast of $0.73. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share.

ALT has been the subject of a number of other reports. Stifel Nicolaus initiated coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective for the company. UBS Group began coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a "buy" rating and a $26.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research report on Monday. Finally, William Blair initiated coverage on Altimmune in a research note on Friday. They issued a "market perform" rating on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Altimmune presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.83.

Altimmune Trading Down 9.9 %

Altimmune stock traded down $0.66 during trading hours on Monday, reaching $5.99. 2,626,613 shares of the company were exchanged, compared to its average volume of 2,252,356. Altimmune has a 12 month low of $5.28 and a 12 month high of $12.35. The stock has a 50-day moving average of $6.85 and a 200 day moving average of $7.20. The firm has a market cap of $426.04 million, a price-to-earnings ratio of -3.86 and a beta of 0.19.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Bellevue Group AG increased its stake in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company's stock valued at $5,303,000 after acquiring an additional 263,660 shares during the period. Virtu Financial LLC bought a new stake in shares of Altimmune during the third quarter valued at approximately $674,000. Barclays PLC raised its stake in shares of Altimmune by 93.0% in the third quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after purchasing an additional 75,064 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock worth $1,299,000 after purchasing an additional 4,772 shares during the period. Finally, Stifel Financial Corp boosted its stake in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company's stock worth $109,000 after buying an additional 7,746 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.